The present disclosure relates to containers that are at least partially prefilled with material that is sensitive to sterilization techniques including but not limited to ethylene oxide (EtO) sterilization.
It is known to prefill containers, including vials and syringes, with material that is sensitive to sterilization techniques. For example, IV flush, drugs, vaccines or other materials may experience a change to their composition or properties when exposed to sterilization. Such changes may include, for example, an undesired shift in pH following EtO sterilization.
Such prefilled containers containing sterilization-sensitive material may be packaged with other materials and/or equipment requiring sterilization. For example, collectively packaged kits such as surgical or procedural kits may include prefilled containers as well as instruments requiring sterilization, among other contents or components necessary to perform a given medical procedure. In such instances where prefilled containers include sterilization-sensitive material and require sterilization, it is known to use glass containers due to the barrier properties of glass.
Conventional solutions may have certain limitations. For example, glass containers may be fragile, may sliver and contaminate the material therein, and may break or chip during shipping and handling. Further, glass is relatively costly to manufacture and transport, and has inherent limitations relating to geometry, size and intricacy of the container.
One method of addressing the known sterilization limits inherent to plastic containers is to attach the non-sterile, prefilled container to the sterile kit post-sterilization; in effect creating a secondary non-sterile kit comprised of a non-sterile prefilled container and a sterile kit. The added step of separately packaging plastic containers may make manufacturing more time consuming and expensive. Separately packaging plastic containers may also reduce the convenience and utility of a surgical kit. Maintaining sterile technique during a procedure becomes more challenging when a separately packaged, non-sterile component must be handled. This may affect the sequence of actions required to complete a given procedure; or, in some cases, the number of physicians needed to complete a procedure.
It is desired to address one or more such limitations experienced with the plastic container systems, packaged kits, and/or methods disclosed herein.
Referring now to the drawings, illustrative examples are shown in detail. Although the drawings represent certain examples, the drawings are not necessarily to scale and certain features may be exaggerated to better illustrate and explain an innovative aspect of an example. Further, the examples described herein are not intended to be exhaustive or otherwise limiting to the precise form and configuration shown in the drawings and disclosed herein.
A prefilled container system may include a syringe assembly having a barrel, plunger and tip cap. A chamber may be formed within the barrel between the plunger and tip cap and may be configured to hold materials such as sterilization sensitive materials. The syringe assembly may be formed of various materials and/or solutions that permit the syringe assembly to be sterilized and packaged with a surgical kit containing other items necessary to perform a medical procedure. For example, as determined by medical professionals such as surgeons and operating room staff, such kits may be tailored to particular procedures and may include items such as instruments, drugs, antiseptics, dressings that are appropriate and needed for the particular procedure. For convenience, it is preferred that individual items not be separately packaged.
For health and sanitary purposes, it may be desired and necessary that all items within the kit be sterilized and ready for use by the medical professionals. During manufacturing, the items within the kit may be sterilized using terminal sterilization. Terminal sterilization methods may include EtO sterilization, autoclaving, or other methods such as irradiation. In one embodiment, terminal sterilization is used as the sole sterilization step in the assembling and manufacturing of the packaged kits. However, as explained above, the EtO gases used during terminal sterilization may alter the composition of the material within a syringe.
Accordingly, a syringe assembly 100, as shown in
The contents of plastic containers, as described above, may be compromised during the kit sterilization process and, therefore, the solution contained therein may be affected and considered “sterilization sensitive.” For example, EtO sterilization may include subjecting the filled syringe assembly 100 to EtO gas. The gas may kill any micro-organisms and ensure that the assembly 100 is sterilized prior to use. The EtO gases may alter the composition of the sterilization sensitive solution. However, as explained below, the syringe assembly 100 provides a chamber 230 capable of creating an effective barrier between the sterilization gases and the solution so that the solution remains substantially unchanged within the chamber 230 during sterilization. Thus, the solution remains within acceptable specifications for the manufacture, sale, and use of the device. For example, if the solution is a drug and it remains substantially unchanged after exposure to sterilization, then the device and solution still meets the regulatory requirements for the manufacture, sale, and use of that drug.
The plunger 110, as shown in
The stopper 125 may be connected to the plunger body 130 via an attachment mechanism 155. In one exemplary arrangement, the attachment mechanism 155, as shown in
The stopper 125 may have relatively a stiff elastic modulus and be formed from one or more materials, including high barrier thermoplastic elastomers. Exemplary elastomers may include, but are not limited to, butyl rubber. The stopper 125 may also be coated for increased barrier properties. The plunger body 130 may include one or more plastic materials. For example, suitable plastics may include injection moldable cyclic olefin polymer (COP) or cyclic olefin copolymer (COC). The base 120 of the plunger 110 may be formed so as to be co-extensive with the plunger body 130 and thus include similar materials. During sterilization, the base 120, and at least a portion of the plunger body 130 may be exposed to EtO gases. However, the plunger body 130 and base 120 may not come into contact with the sterilization sensitive material within the chamber 230. Thus, at least one of the base 120 and plunger body 130 may be formed of less expensive plastics such as polypropylene or polycarbonate.
The barrel 105, as shown in
The barrel 105 may also include a mechanical engagement system, or barrel flange 210, extending radially inwardly of an inner surface of the barrel 105 adjacent the first end 180. During EtO sterilization, a pressure differential may be created within the barrel 105. This differential may apply a force against the plunger 110, attempting to force the plunger 110 out of the barrel 105. The barrel flange 210 may be configured to engage the outer periphery of a plunger flange 170 and/or the wipers 150 of the stopper 125 to prevent the plunger 110 from expulsion from the barrel 105. In one exemplary method, an air bubble is intentionally left within the barrel after filling the chamber 230 with solution. The air bubble facilitates a large pressure differential and outward force of the plunger 110 during sterilization. As this outward force increases, so does the contact pressure between at least one of the stopper 125 and the plunger flange 170 and the barrel flange 210, increasing effectiveness of the mechanical seal to isolate the contained solution. In another exemplary method, the chamber 230 is free of air bubbles. Other exemplary mechanical engagements may include one or more protrusions on an inner surface of the barrel 105 that are sufficient to prevent expulsion of the plunger 115.
The barrel 105 may include one or more plastic materials. Barrel 105 composition may include COP and/or COC materials. These polymers may be very similar to glass having high gas impermeability, high moisture barrier and low absorption rate properties. The barrel 105 may be coated with materials for increased barrier properties, such as silicone dioxide or aluminum dioxide. In another embodiment, the barrel 105 may be uncoated. Additionally or alternatively, the barrel 105 may be formed from materials having high clarity so that contents of the barrel may be visibly inspected. The barrel 105 may also be formed from materials having at least one of low water vapor permeability (in one example, less than about 0.5 g·mm/m2·d to minimize moisture transmission across walls of the container), low oxygen permeability (in one example, less than about 500 cm3·mm/m2·d·bar to minimize gas transmission across walls of the container), high heat resistance to withstand temperatures of autoclaving (in one example, the heat resistance is effective to standard autoclaving temperatures), and minimal leaching, elution, extraction, absorption or adsorption.
The barrel 105 may be configured to receive the plunger 110 at the barrel first end 180. The stopper 125 of the plunger 110 may be inserted at the first end 180. The stopper 125, along with the tip cap 115, may be configured to create the chamber 230 within the barrel 105. As explained above, the stopper 125 may have a relatively stiff elastic modulus and the wipers 150 may create a mating surface with the inside of the barrel 105. Thus, the stopper 125 may permit the plunger 110 to move along axis A within the barrel 105 and also create a seal within the barrel 105 to prevent any material from leaving the chamber 230. Moreover, the mating conical surfaces between the barrel 105 and the stopper 125 may also serve to prevent blood uptake after the prefilled syringe has been administered to a patient by preventing the plunger assembly 110 from recoiling upward after administration.
Referring again to
The tip cap 115 may be made of any number of materials. Exemplary materials may include polycarbonates that possess adequate barrier properties. For example, plastics such as polypropylene coated with a high-barrier material (e.g., butyl rubber) on at least a portion of the tip cap 115 may be used. The surface area of the tip cap 115 exposed to the material in the chamber 230 is relatively small compared to that of the barrel 105 and stopper 125. Thus, the portion exposed to the material may be coated, while the remaining portions of the tip cap 115 may not.
As explained, the outside of the syringe assembly 100 and/or the vial 240 may be sterilized along with the other items within a surgical kit via a variety of sterilization techniques such as EtO sterilization and/or autoclaving. Prior to sterilization, the separate components of the syringe assembly 100 and the vial 240 (e.g., the barrel 105, plunger 110, tip cap 115, etc.) may be manufactured in a clean room environment. Additionally or alternatively, each component may be sterilized prior to assembly. Upon partial assembly of the components, the chamber 230 may be filled with the material. In one example, the stopper 125 of the plunger 110 may be inserted at the first end 180 of the barrel 105 and prior to attaching the tip cap 115 to the barrel neck 195, the material may be filled at the opening 205. The tip cap 115 may then be attached to the barrel 105 at the barrel neck 195, thus sealing the material within the chamber 230. In another example, the tip cap 115 may first be connected to the barrel neck 195 via the luer fitting and the material may be filled at the first end 180 prior to the plunger 110 being inserted into the barrel 105. Once the chamber 230 has been filled, and the plunger 110 inserted, the syringe assembly 100 may be sterilized. For example, the assembly 100 may be placed in an autoclave. By subjecting the syringe assembly 100 to highly saturated steam, the exterior and interior of the components may be sterilized. Once the syringe assembly 100 is removed from the autoclave, the outside of the assembly 100 may become non-sterile; however, the fluid and fluid path remain sterile. The syringe assembly 100 may then be combined with the remaining kit contents. The entire kit may then be sterilized via EtO sterilization. Thus, the outside of the assembly 100 is sterilized and packaged with the rest of the kit items. Due to the specific properties of the barrel 105, plunger 110, stopper 125, and tip cap 115, the material within the chamber 230 is not altered or affected by the sterilization process.
Advantageously, prefilled container systems may be packaged together with other materials requiring terminal sterilization as part of the manufacturing process and need not be separately packaged with materials having high barrier properties such as sealed, foil wrapping.
With regard to the processes, systems, methods, heuristics, etc. described herein, it should be understood that, although the steps of such processes, etc. have been described as occurring according to a certain ordered sequence, such processes could be practiced with the described steps performed in an order other than the order described herein. It further should be understood that certain steps could be performed simultaneously, that other steps could be added, or that certain steps described herein could be omitted. In other words, the descriptions of processes herein are provided for the purpose of illustrating certain embodiments, and should in no way be construed so as to limit the claimed invention.
Accordingly, it is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments and applications other than the examples provided would be apparent upon reading the above description. The scope of the invention should be determined, not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. It is anticipated and intended that future developments will occur in the arts discussed herein, and that the disclosed systems and methods will be incorporated into such future embodiments. In sum, it should be understood that the invention is capable of modification and variation and is limited only by the following claims.
All terms used in the claims are intended to be given their broadest reasonable constructions and their ordinary meanings as understood by those skilled in the art unless an explicit indication to the contrary in made herein. In particular, use of the singular articles such as “a,” “the,” “said,” etc. should be read to recite one or more of the indicated elements unless a claim recites an explicit limitation to the contrary.
This application is a continuation of U.S. patent application Ser. No. 13/804,557, filed Mar. 14, 2013, which claims priority to U.S. Provisional Patent Application No. 61/643,603, filed May 7, 2012, the contents of which are incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3630665 | Andersen | Dec 1971 | A |
3878664 | Zinke | Apr 1975 | A |
3993751 | Zinke | Nov 1976 | A |
4018222 | McAleer | Apr 1977 | A |
4106622 | Windischman | Aug 1978 | A |
4474734 | Cooper | Oct 1984 | A |
4522302 | Paikoff | Jun 1985 | A |
4635807 | Knapp | Jan 1987 | A |
4739881 | Bruso | Apr 1988 | A |
5061281 | Mares | Oct 1991 | A |
5342673 | Bowman | Aug 1994 | A |
5358475 | Mares | Oct 1994 | A |
5382406 | Kruger | Jan 1995 | A |
5597530 | Smith | Jan 1997 | A |
5620425 | Heffernan | Apr 1997 | A |
5741236 | Kakiuti | Apr 1998 | A |
5803918 | Vetter | Sep 1998 | A |
6033369 | Goldenberg | Mar 2000 | A |
6161364 | Kolberg | Dec 2000 | A |
6164044 | Porfano | Dec 2000 | A |
6189195 | Reilly | Feb 2001 | B1 |
6193688 | Balestracci | Feb 2001 | B1 |
6231810 | Tunc | May 2001 | B1 |
6331174 | Reinhard | Dec 2001 | B1 |
6458095 | Wirt | Oct 2002 | B1 |
6475140 | Konstorum | Nov 2002 | B1 |
6719733 | Heffernan | Apr 2004 | B1 |
7998120 | Sano | Aug 2011 | B2 |
8252228 | Freeman | Aug 2012 | B1 |
20020051730 | Bodnar | May 2002 | A1 |
20020119074 | McGowan, Jr. | Aug 2002 | A1 |
20020172615 | Woodworth | Nov 2002 | A1 |
20030034264 | Hamai | Feb 2003 | A1 |
20030100866 | Reynolds | May 2003 | A1 |
20030159969 | McMichael | Aug 2003 | A1 |
20040187438 | Clarke | Sep 2004 | A1 |
20050075611 | Hetzler | Apr 2005 | A1 |
20050089442 | Young | Apr 2005 | A1 |
20050101905 | Merry | May 2005 | A1 |
20050268573 | Yan | Dec 2005 | A1 |
20060260967 | Clarke | Nov 2006 | A1 |
20070003584 | Anderson | Jan 2007 | A1 |
20070048251 | Arthur | Mar 2007 | A1 |
20070048337 | Arthur | Mar 2007 | A1 |
20070082859 | Stover | Apr 2007 | A1 |
20080081763 | Swetlin | Apr 2008 | A1 |
20090145876 | Kawamura | Jun 2009 | A1 |
20090281504 | Nanba | Nov 2009 | A1 |
20100106096 | Hirokane | Apr 2010 | A1 |
20100112063 | Figuly | May 2010 | A1 |
20100234810 | Arai | Sep 2010 | A1 |
20100298779 | Hetzler | Nov 2010 | A1 |
20100313962 | Bondar | Dec 2010 | A1 |
20100331864 | Shetty | Dec 2010 | A1 |
20110174647 | Shimazaki | Jul 2011 | A1 |
20110276005 | Hioki | Nov 2011 | A1 |
20120035129 | Wagman | Feb 2012 | A1 |
20120093803 | Altrichter | Apr 2012 | A1 |
20120094955 | Wagman | Apr 2012 | A1 |
20120121532 | Goessl | May 2012 | A1 |
20130032967 | Wang | Feb 2013 | A1 |
20130103023 | Monson | Apr 2013 | A1 |
20130110025 | Donnellan | May 2013 | A1 |
20130280346 | Powers | Oct 2013 | A1 |
20130296779 | Kuehne | Nov 2013 | A1 |
20140004253 | Ruane | Jan 2014 | A1 |
20140262883 | Devouassoux | Sep 2014 | A1 |
20140342954 | Ingber | Nov 2014 | A1 |
20150174338 | Takemoto | Jun 2015 | A1 |
20150306282 | Scanlon | Oct 2015 | A1 |
20160135895 | Faasse | May 2016 | A1 |
20160200461 | Broadbent | Jul 2016 | A1 |
20170333641 | Bamberg | Nov 2017 | A1 |
20170349313 | Kuehne | Dec 2017 | A1 |
20180105294 | Abboud | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
0079676 | May 1983 | EP |
1930040 | Jun 2008 | EP |
2374497 | Oct 2011 | EP |
2500092 | Sep 2013 | GB |
H0394766 | Apr 1991 | JP |
H0788151 | Apr 1995 | JP |
H09285540 | Nov 1997 | JP |
2002505921 | Feb 2002 | JP |
2002219170 | Aug 2002 | JP |
2003526438 | Sep 2003 | JP |
2004530465 | Oct 2004 | JP |
2006271461 | Oct 2006 | JP |
2007507308 | Mar 2007 | JP |
2008525136 | Jul 2008 | JP |
2009207619 | Sep 2009 | JP |
2015515480 | May 2015 | JP |
2015519125 | Jul 2015 | JP |
2015521530 | Jul 2015 | JP |
2018513741 | May 2018 | JP |
9945985 | Sep 1999 | WO |
2005032627 | Apr 2005 | WO |
2006029528 | Mar 2006 | WO |
2007024957 | Mar 2007 | WO |
2008077155 | Jun 2008 | WO |
Entry |
---|
0.9% Sodium Chloride Injection, USP, Jun. 2014, Hospira Inc. (Year: 2014). |
AAM I, AAM I TI R56: 2013 Guidance for the development, validation and routine control of an ethylene oxide sterilization process utilizing flexible bag systems for the sterilization of medical devices, Dec. 27, 2013, Association for the ADvancement of Medical Instrumentation (Year: 2013). |
Bateman, Relative Humidity and the Killing of Bacteria, May 10, 1961 (Year: 1961). |
Cyclo Olefin Polymer (COP) Zeonex; Jun. 2012; pp. 1-15. |
Daryl L. Woodman, Determination of Spore Lethality at low Ethylene Oxide Gas Concentrations at Atmospheric Pressure, Jul. 7, 2011, Andersen Scientific Inc. (Year: 2011). |
Ernst, Ethylene Oxide Gaseous Sterilization for Industrial Applications, 1972, Duke University Press (Year: 1972). |
Extended European Search Report from corresponding European Patent Application No. 17807234.4 dated Sep. 10, 2020; 9 pages. |
Federal Register, vol. 43, No. 122, Jun. 23, 1978, pp. 27 47 4-27 480 (Year: 1978). |
Food Safety and Inspection Service, Food Safety Information, Oct. 2011, USDA (Year: 2011). |
Gisela C.C. Mendes, Ethylene oxide sterilization of medical devices: A review, Nov. 2007, AJIC: American Journal of Infection Control, Federal Register, vol. 43, No. 122 (Year: 2007). |
International Search Report and Written Opinion for PCT/US2013/039884, dated Sep. 30, 2013 (18 pages). |
International Search Report and Written Opinion from PCT/US17/33719, dated Jul. 20, 2017 (17 pages). |
International Search Report and Written Opinion from PCT/US2013/039884, dated Sep. 20, 2013 (18 pages). |
Japan Medical Devices Society, Guideline for Sterility Assurance in Healthcare Settings 2015, dated May 25, 2015, 37 pages. |
Japanese Office Action with English translation from related Japanese Patent Application No. 2018-563068 dated Jan. 12, 2021; 10 pages. |
Lucas, Residual Ethylene Oxide in Medical Devices and Device Material, Jan. 8, 2003. |
M D+DI, EtO Sterilization: Principles of Process Design, Dec. 1, 1998, Medical Device and Diagnostic Industry, https://www.mddionline.com/eto-sterilization-principles-process-design (Year: 1998). |
Michael N. Eakins; New Plastics for Old Vials; Jun. 2005; pp. 52-57. |
Moldenhauer, “Chapter 12: Sterlization Processes,” Contamination Control in Healthcare Product Manufacturing vol. 2, edited by Madsen and Moldenhauer, PDA-DHI, 2014, pp. 1-79, p. 23 para 3. |
Office of Air Quality Planning and Standards, Ethylene Oxide Commercial Sterilization and Fumigation Operations Neshap Implementation Document, Mar. 2004, EPA (Year: 2004). |
PCT International Search Report and Written Opinion dated Jul. 20, 2017 for PCT/US17133719. |
The Free Dictionary by Farlex (accessed Apr. 24, 2022), https://www.thefreedictionary.com/sensitive; 1 page. |
Wattal et al., “Chapter 10: Decontamination and Sterlization Procedures,” Hospital Infection Prevention: Principles I:md Practices, edited by Khardori, Springer, Oct. 30, 2013, pp. 103-120; p. 113 col. 1 para 4. |
Zhang Tongcheng, “Quality control and evaluation of sterile medical devices,” Soochow University Press (2012). |
Number | Date | Country | |
---|---|---|---|
20200376202 A1 | Dec 2020 | US |
Number | Date | Country | |
---|---|---|---|
61643603 | May 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13804557 | Mar 2013 | US |
Child | 16996165 | US |